Lara K. Leister

Design of amidobenzimidazole STING receptor agonists with systemic activity

Joshi M. Ramanjulu, G. Scott Pesiridis, Jingsong Yang et al. · Nature · 2018 · 803 citations

Systemic Activity, Medicine, Mechanism Of Action +4

Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases

Philip A. Harris, Scott B. Berger, Jae Uk Jeong et al. · Journal of Medicinal Chemistry · 2017 · 464 citations · Full text

Drug Target, Immunology, Cell Death +22

Potent, Orally Bioavailable Delta Opioid Receptor Agonists for the Treatment of Pain: Discovery of<i>N</i>,<i>N</i>-Diethyl-4-(5-hydroxyspiro[chromene-2,4′-piperidine]-4-yl)benzamide (ADL5859)

Bertrand Le Bourdonnec, Rolf T. Windh, Christopher W. Ajello et al. · Journal of Medicinal Chemistry · 2008 · 89 citations · Full text

Spirocyclic Delta Opioid Receptor Agonists for the Treatment of Pain: Discovery of<i>N</i>,<i>N</i>-Diethyl-3-hydroxy-4-(spiro[chromene-2,4′-piperidine]-4-yl) Benzamide (ADL5747)

Bertrand Le Bourdonnec, Rolf T. Windh, Lara K. Leister et al. · Journal of Medicinal Chemistry · 2009 · 83 citations · Full text

Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer

Philip A. Harris, Jill M. Marinis, John D. Lich et al. · ACS Medicinal Chemistry Letters · 2019 · 79 citations · Full text